BibTex format
@inproceedings{Lythgoe:2022:10.1136/jitc-2022-SITC2022.0627,
author = {Lythgoe, M and Mullish, B and Frampton, A and Dama, P and Pickford, E and Tookman, L and Cunnea, P and Fotopoulou, C and Jeffery, I and Fyvie, G and Stevenson, A and Krell, J},
doi = {10.1136/jitc-2022-SITC2022.0627},
pages = {A659--A659},
publisher = {BMJ PUBLISHING GROUP},
title = {ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY},
url = {http://dx.doi.org/10.1136/jitc-2022-SITC2022.0627},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - CPAPER
AU - Lythgoe,M
AU - Mullish,B
AU - Frampton,A
AU - Dama,P
AU - Pickford,E
AU - Tookman,L
AU - Cunnea,P
AU - Fotopoulou,C
AU - Jeffery,I
AU - Fyvie,G
AU - Stevenson,A
AU - Krell,J
DO - 10.1136/jitc-2022-SITC2022.0627
EP - 659
PB - BMJ PUBLISHING GROUP
PY - 2022///
SP - 659
TI - ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY
UR - http://dx.doi.org/10.1136/jitc-2022-SITC2022.0627
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000919423400588&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
ER -